Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.

@article{CalvoRo2016AntiInterleukin6RT,
  title={Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients.},
  author={Vanesa Calvo-R{\'i}o and Montserrat Santos-G{\'o}mez and I. Pe{\~n}uelas Calvo and Maria Isabel Gonzalez-Fernandez and Berta L{\'o}pez-Montesinos and Mª Engracia P{\'e}rez Mesquida and Alfredo M Adan and Mar{\'i}a Victoria Hern{\'a}ndez and Olga Ma{\'i}z and Antonio Atanes and Beatriz N avarro Bravo and Consuelo Modesto and Gisela D{\'i}az-Cordov{\'e}s and Natalia Palmou-Fontana and Javier Loricera and Mar{\'i}a del Carmen Gonz{\'a}lez-Vela and Rosal{\'i}a Demetrio-Pablo and Jos{\'e} Luis Mart{\'i}nez Hern{\'a}ndez and Miguel A Gonz{\'a}lez-Gay and Ricardo Blanco},
  journal={Arthritis & rheumatology},
  year={2016},
  volume={69 3},
  pages={
          668-675
        }
}
OBJECTIVE To assess the efficacy of tocilizumab (TCZ) for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis. METHODS We conducted a multicenter study of patients with JIA-associated uveitis that was refractory to conventional immunosuppressive drugs and anti-tumor necrosis factor (anti-TNF) agents. RESULTS We assessed 25 patients (21 female; 47 affected eyes) with a mean ± SD age of 18.5 ± 8.3 years. Uveitis was bilateral in 22 patients. Cystoid macular edema was… CONTINUE READING
BETA

Similar Papers

Loading similar papers…